Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients - Trial NCT02809573
Access comprehensive clinical trial information for NCT02809573 through Pure Global AI's free database. This Phase 1 trial is sponsored by Chipscreen Biosciences, Ltd. and is currently Completed. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Chipscreen Biosciences, Ltd.
Timeline & Enrollment
Phase 1
Aug 11, 2016
Jan 08, 2019
Primary Outcome
dose-limiting toxicity (DLT)
Summary
The purpose of this dose-escalation study is to assess the safety and tolerability of
 treatment with Chidamide in a range of doses combined with CHOP in fixed dose in patients
 with newly diagnosed peripheral T-cell lymphoma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT02809573
Non-Device Trial